Haijin Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haijin Zhao has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Zhaoqian Gong
Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University
11 shared publications- Wenqu Zhao
Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, NanFang Hospital, Southern Medical University, Guangzhou, 510515, China
9 shared publications Wenqu Zhao
Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University
8 shared publicationsYanyan Ma
Shenzhen Longgang District People's Hospital, Shenzhen, 518055, China
7 shared publicationsJunwen Huang
Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangdong, 510515, China
6 shared publicationsMaosheng Xu
Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangdong 510515, China
6 shared publications
Latest Publications
- 29 September 2026
- Published by Taylor & Francis in Journal of Asthma
- p. 1-10
Unraveling the “anxiety–adherence paradox”: illness perception clusters predict non–adherence in newly diagnosed asthma
Asthma is a heterogeneous chronic airway disease presenting a substantial global health challenge (1). While effective management is centered on inhaled corticosteroid (ICS)-containing therapy for ...
- 29 September 2026
- Published by Taylor & Francis in Journal of Asthma
- p. 1-10
Unraveling the “anxiety–adherence paradox”: illness perception clusters predict non–adherence in newly diagnosed asthma
Asthma is a heterogeneous chronic airway disease presenting a substantial global health challenge (1). While effective management is centered on inhaled corticosteroid (ICS)-containing therapy for ...
- Open Access
- 27 June 2026
- Published by Elsevier in Redox Biology
- Vol. 95, 104280
Histidine metabolic reprogramming drives oxidative stress induced mtDNA release to promote necroptosis and airway inflammation in severe asthma
- 27 June 2026
- Published by Elsevier in Redox Biology
- Vol. 95, 104280
Open AccessHistidine metabolic reprogramming drives oxidative stress induced mtDNA release to promote necroptosis and airway inflammation in severe asthma
- Open Access
- 25 May 2026
- Published by Elsevier in Redox Biology
- Vol. 94, 104232
Cannabichromeorcin targets cathepsin L to alleviate oxidative stress–Driven airway inflammation in severe asthma
- 25 May 2026
- Published by Elsevier in Redox Biology
- Vol. 94, 104232
Open AccessCannabichromeorcin targets cathepsin L to alleviate oxidative stress–Driven airway inflammation in severe asthma
- Open Access
- 1 May 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (5) , 511
Clinical characteristics, symptom burden, and pulmonary function trajectories of spirometry- and MMEF-defined bronchodilator responsiveness in COPD: a single-center prospective study
Background: Bronchodilator responsiveness (BDR) is a common indicator in chronic obstructive pulmonary disease (COPD), but its clinical relevance remains controversial. Traditional spirometry may fail to detect small airway reversibility, which can be captured by maximum mid-expiratory flow (MMEF). The clinical significance of combined-BDR (integrating spirometric indices and MMEF) in guiding phenotype-based and individualized COPD management under current Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations remains unclear. This study aimed to investigate the clinical significance of combined-BDR in patients with COPD. Methods: In this single-center prospective study, a total of 137 patients with stable COPD were enrolled [post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) 1 or FVC and/or ≥30% increase in MMEF post-bronchodilator. Symptoms [COPD Assessment Test (CAT), modified Medical Research Council (mMRC) dyspnea scale, and St. George’s Respiratory Questionnaire for COPD (SGRQ-C)], lung function, and moderate-to-severe exacerbations were assessed at baseline and 12 months. Multivariable regression and linear mixed-effects models were used to evaluate the associations between combined-BDR and clinical outcomes. Results: Of 137 patients, 49 (35.8%) exhibited Combined-BDR, while 88 (64.2%) did not. Baseline demographic characteristics, including age, sex, body mass index (BMI), smoking status, and fractional exhaled nitric oxide (FeNO) levels, were comparable between the two groups. Patients with combined-BDR had significantly higher mMRC scores (Pvs. 9.26±5.71, P=0.02), and lower baseline FEV1 (1.32±0.45 vs. 1.78±0.72 L, P1 [adjusted mean difference 0.12 L, 95% confidence interval (CI): 0.02–0.21, P=0.02] and FVC (adjusted mean difference 0.22 L, 95% CI: 0.04–0.39, P=0.02). Conclusions: Combined-BDR identifies a distinct COPD phenotype characterized by a higher baseline symptom burden but greater functional improvement following inhaled therapy, highlighting its potential value for phenotype-guided and individualized disease management.
- 1 May 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (5) , 511
Open AccessClinical characteristics, symptom burden, and pulmonary function trajectories of spirometry- and MMEF-defined bronchodilator responsiveness in COPD: a single-center prospective study
Background: Bronchodilator responsiveness (BDR) is a common indicator in chronic obstructive pulmonary disease (COPD), but its clinical relevance remains controversial. Traditional spirometry may fail to detect small airway reversibility, which can be captured by maximum mid-expiratory flow (MMEF). The clinical significance of combined-BDR (integrating spirometric indices and MMEF) in guiding phenotype-based and individualized COPD management under current Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations remains unclear. This study aimed to investigate the clinical significance of combined-BDR in patients with COPD. Methods: In this single-center prospective study, a total of 137 patients with stable COPD were enrolled [post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) 1 or FVC and/or ≥30% increase in MMEF post-bronchodilator. Symptoms [COPD Assessment Test (CAT), modified Medical Research Council (mMRC) dyspnea scale, and St. George’s Respiratory Questionnaire for COPD (SGRQ-C)], lung function, and moderate-to-severe exacerbations were assessed at baseline and 12 months. Multivariable regression and linear mixed-effects models were used to evaluate the associations between combined-BDR and clinical outcomes. Results: Of 137 patients, 49 (35.8%) exhibited Combined-BDR, while 88 (64.2%) did not. Baseline demographic characteristics, including age, sex, body mass index (BMI), smoking status, and fractional exhaled nitric oxide (FeNO) levels, were comparable between the two groups. Patients with combined-BDR had significantly higher mMRC scores (Pvs. 9.26±5.71, P=0.02), and lower baseline FEV1 (1.32±0.45 vs. 1.78±0.72 L, P1 [adjusted mean difference 0.12 L, 95% confidence interval (CI): 0.02–0.21, P=0.02] and FVC (adjusted mean difference 0.22 L, 95% CI: 0.04–0.39, P=0.02). Conclusions: Combined-BDR identifies a distinct COPD phenotype characterized by a higher baseline symptom burden but greater functional improvement following inhaled therapy, highlighting its potential value for phenotype-guided and individualized disease management.
- Open Access
- 8 April 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (4) , 463
Nrp1 Signaling Reprograms Glutathione Metabolism to Drive Mitochondrial Dysfunction in Severe Asthma
Mitochondrial dysfunction drives persistent inflammation in severe asthma, yet its upstream metabolic regulation remains unclear. Induced sputum from patients with severe asthma was analyzed and integrated with transcriptomic datasets from independent cohorts. Two mouse models (C57BL/6J) were used for in vivo validation with multi-omics profiling, and mechanistic studies were performed in air–liquid interface-cultured primary human airway epithelial cells. Glutathione reduced form (GSHr) was markedly depleted in sputum and associated with poor disease control and mixed granulocytic inflammation in patients with severe asthma. Multi-omics analyses revealed coordinated disruption of glutathione (GSH) metabolism, including oxidized GSH accumulation, reduced synthesis and glutathione-S-transferase activity, and impaired mitochondrial GSH transport. GSH supplementation alleviated airway inflammation, oxidative stress, and mitochondrial dysfunction, whereas pharmacological inhibition of GST exacerbated these effects. Mitochondrial analyses identified suppressed SLC25A39 expression as a key mediator of defective GSH transport and redox imbalance. Transcriptomic profiling of airway biopsies showed upregulation of Neuropilin-1 (Nrp1), closely associated with altered glutathione pathways. Targeting the Nrp1 b1 domain restored mitochondrial GSH metabolism and attenuated airway inflammation. These findings identify an Nrp-centered metabolic pathway that disrupts mitochondrial homeostasis and drives inflammatory amplification, highlighting mitochondria-targeted therapeutic strategies for severe asthma.
- 8 April 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (4) , 463
Open AccessNrp1 Signaling Reprograms Glutathione Metabolism to Drive Mitochondrial Dysfunction in Severe Asthma
Mitochondrial dysfunction drives persistent inflammation in severe asthma, yet its upstream metabolic regulation remains unclear. Induced sputum from patients with severe asthma was analyzed and integrated with transcriptomic datasets from independent cohorts. Two mouse models (C57BL/6J) were used for in vivo validation with multi-omics profiling, and mechanistic studies were performed in air–liquid interface-cultured primary human airway epithelial cells. Glutathione reduced form (GSHr) was markedly depleted in sputum and associated with poor disease control and mixed granulocytic inflammation in patients with severe asthma. Multi-omics analyses revealed coordinated disruption of glutathione (GSH) metabolism, including oxidized GSH accumulation, reduced synthesis and glutathione-S-transferase activity, and impaired mitochondrial GSH transport. GSH supplementation alleviated airway inflammation, oxidative stress, and mitochondrial dysfunction, whereas pharmacological inhibition of GST exacerbated these effects. Mitochondrial analyses identified suppressed SLC25A39 expression as a key mediator of defective GSH transport and redox imbalance. Transcriptomic profiling of airway biopsies showed upregulation of Neuropilin-1 (Nrp1), closely associated with altered glutathione pathways. Targeting the Nrp1 b1 domain restored mitochondrial GSH metabolism and attenuated airway inflammation. These findings identify an Nrp-centered metabolic pathway that disrupts mitochondrial homeostasis and drives inflammatory amplification, highlighting mitochondria-targeted therapeutic strategies for severe asthma.
- 3 January 2026
- Published by Springer Nature in Lung
- Vol. 204 (1) , 2
Sputum Eosinophils Predict Annual Remission of the Frequent Exacerbator Phenotype in COPD: A Prospective Cohort Study
The frequent-exacerbator (FE) phenotype guides COPD management, yet its year-to-year stability and the role of airway eosinophilia in FE remission are uncertain. In a single-center prospective cohort (n = 289), patients were classified as FE (≥ 2 moderate or ≥ 1 severe exacerbation in the prior year; n = 88) or non-FE (n = 201) and followed 12 months. FE patients were labeled FE-persistent or FE-remitted at 1 year. Clinical data, spirometry, CT, fractional exhaled nitric oxide (FeNO), blood counts, and induced-sputum cytology were collected. Logistic regression identified correlates of remission; ROC/AUC with bootstrap validation and calibration assessed models. FE prevalence was 30.4%; 58.0% of FE patients remitted. Compared with non-FE, FE had higher SE% and more eosinophilic/mixed sputum phenotypes. Within FE, remitters had better lung function and greater airway eosinophilia. Each 1% SE% increase independently predicted remission (OR 1.21, 95% CI 1.03-1.47); SE% ≥ 3% tripled the odds (OR 3.76, 95% CI 1.29-11.91). Prior severe exacerbations and CT-defined chronic bronchitis predicted persistence (ORs 0.21-0.27). Models showed good discrimination (AUC 0.785-0.799; bootstrap-corrected 0.750-0.773) and calibration (Brier 0.179). FE status is dynamic; over half remit within a year. Airway eosinophilia-especially SE% ≥ 3%-independently associates with FE remission, while prior severe exacerbations and CT-chronic bronchitis indicate persistence. Incorporating sputum cytology with history and imaging may enable earlier re-stratification and treatable-trait-guided COPD care.
- 3 January 2026
- Published by Springer Nature in Lung
- Vol. 204 (1) , 2
Sputum Eosinophils Predict Annual Remission of the Frequent Exacerbator Phenotype in COPD: A Prospective Cohort Study
The frequent-exacerbator (FE) phenotype guides COPD management, yet its year-to-year stability and the role of airway eosinophilia in FE remission are uncertain. In a single-center prospective cohort (n = 289), patients were classified as FE (≥ 2 moderate or ≥ 1 severe exacerbation in the prior year; n = 88) or non-FE (n = 201) and followed 12 months. FE patients were labeled FE-persistent or FE-remitted at 1 year. Clinical data, spirometry, CT, fractional exhaled nitric oxide (FeNO), blood counts, and induced-sputum cytology were collected. Logistic regression identified correlates of remission; ROC/AUC with bootstrap validation and calibration assessed models. FE prevalence was 30.4%; 58.0% of FE patients remitted. Compared with non-FE, FE had higher SE% and more eosinophilic/mixed sputum phenotypes. Within FE, remitters had better lung function and greater airway eosinophilia. Each 1% SE% increase independently predicted remission (OR 1.21, 95% CI 1.03-1.47); SE% ≥ 3% tripled the odds (OR 3.76, 95% CI 1.29-11.91). Prior severe exacerbations and CT-defined chronic bronchitis predicted persistence (ORs 0.21-0.27). Models showed good discrimination (AUC 0.785-0.799; bootstrap-corrected 0.750-0.773) and calibration (Brier 0.179). FE status is dynamic; over half remit within a year. Airway eosinophilia-especially SE% ≥ 3%-independently associates with FE remission, while prior severe exacerbations and CT-chronic bronchitis indicate persistence. Incorporating sputum cytology with history and imaging may enable earlier re-stratification and treatable-trait-guided COPD care.
- 22 September 2025
- Published by Elsevier in Cellular Signalling
- Vol. 136, 112149
SIRT5 regulates fatty acid oxidation and mitochondrial oxidative stress to exacerbate airway inflammation in experimental asthma
- 22 September 2025
- Published by Elsevier in Cellular Signalling
- Vol. 136, 112149
SIRT5 regulates fatty acid oxidation and mitochondrial oxidative stress to exacerbate airway inflammation in experimental asthma
- 8 July 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 162, 115181
YTHDF1-mediated mitochondrial dysfunction and allergic airway inflammation by interaction with β-catenin/TCF4 signaling
- 8 July 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 162, 115181
YTHDF1-mediated mitochondrial dysfunction and allergic airway inflammation by interaction with β-catenin/TCF4 signaling
- 4 January 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 228, 207-220
Targeting PGAM5 attenuates airway inflammation in asthma by inhibiting HMGB1 release in bronchial epithelium
- 4 January 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 228, 207-220
Targeting PGAM5 attenuates airway inflammation in asthma by inhibiting HMGB1 release in bronchial epithelium